Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

563 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
Handelsman Y, Mathieu C, Del Prato S, Johnsson E, Kurlyandskaya R, Iqbal N, Garcia-Sanchez R, Rosenstock J. Handelsman Y, et al. Among authors: del prato s. Diabetes Obes Metab. 2019 Apr;21(4):883-892. doi: 10.1111/dom.13594. Epub 2019 Jan 3. Diabetes Obes Metab. 2019. PMID: 30499237 Free PMC article. Clinical Trial.
ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations.
Lebovitz HE, Austin MM, Blonde L, Davidson JA, Del Prato S, Gavin JR 3rd, Handelsman Y, Jellinger PS, Levy P, Riddle MC, Roberts VL, Siminerio LM; ACE/AACE Diabetes Recommendations Implementation Writing Committee. Lebovitz HE, et al. Among authors: del prato s. Endocr Pract. 2006 Jan-Feb;12 Suppl 1:6-12. doi: 10.4158/EP.12.S1.6. Endocr Pract. 2006. PMID: 16627372 No abstract available.
Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
Ceriello A, Del Prato S, Bue-Valleskey J, Beattie S, Gates J, de la Peña A, Malone J. Ceriello A, et al. Among authors: del prato s. J Diabetes Complications. 2007 Jan-Feb;21(1):20-7. doi: 10.1016/j.jdiacomp.2005.11.005. J Diabetes Complications. 2007. PMID: 17189870 Clinical Trial.
beta-cell function and anti-diabetic pharmacotherapy.
Del Prato S, Bianchi C, Marchetti P. Del Prato S, et al. Diabetes Metab Res Rev. 2007 Oct;23(7):518-27. doi: 10.1002/dmrr.770. Diabetes Metab Res Rev. 2007. PMID: 17883249 Review.
Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.
Nauck MA, Del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze M, Parikh SJ. Nauck MA, et al. Among authors: del prato s. Diabetes Care. 2011 Sep;34(9):2015-22. doi: 10.2337/dc11-0606. Epub 2011 Aug 4. Diabetes Care. 2011. PMID: 21816980 Free PMC article. Clinical Trial.
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M, Rosenstock J, Endahl LA, Francisco AM, Hollander P; NN1250-3582 (BEGIN BB T2D) Trial Investigators. Garber AJ, et al. Among authors: del prato s. Lancet. 2012 Apr 21;379(9825):1498-507. doi: 10.1016/S0140-6736(12)60205-0. Lancet. 2012. PMID: 22521072 Clinical Trial.
563 results